Moreover, the exploration of new targets, such as Fc receptor-homolog 5 (FcRH5) (also known as FcRL5, IRTA2, or CD307), can potentially expand the repertoire of CAR-T therapies for MM [92]. The gene discussed is FCRL5; the disease is Miyoshi myopathy.